DE60012711D1 - Adjuvanszusammensetzungen zur erhöhung der immunantwort auf polynukleotid-basierende impfstoffe - Google Patents

Adjuvanszusammensetzungen zur erhöhung der immunantwort auf polynukleotid-basierende impfstoffe

Info

Publication number
DE60012711D1
DE60012711D1 DE60012711T DE60012711T DE60012711D1 DE 60012711 D1 DE60012711 D1 DE 60012711D1 DE 60012711 T DE60012711 T DE 60012711T DE 60012711 T DE60012711 T DE 60012711T DE 60012711 D1 DE60012711 D1 DE 60012711D1
Authority
DE
Germany
Prior art keywords
polynucleotide
immune response
adjuvan
compositions
increasing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60012711T
Other languages
English (en)
Other versions
DE60012711T2 (de
Inventor
J Wheeler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fresh Tracks Therapeutics Inc
Original Assignee
Vical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vical Inc filed Critical Vical Inc
Application granted granted Critical
Publication of DE60012711D1 publication Critical patent/DE60012711D1/de
Publication of DE60012711T2 publication Critical patent/DE60012711T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/802—Virus-based particle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60012711T 1999-03-26 2000-03-24 Adjuvanszusammensetzungen zur erhöhung der immunantwort auf polynukleotid-basierende impfstoffe Expired - Lifetime DE60012711T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12634099P 1999-03-26 1999-03-26
US126340P 1999-03-26
PCT/US2000/008282 WO2000057917A2 (en) 1999-03-26 2000-03-24 Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines

Publications (2)

Publication Number Publication Date
DE60012711D1 true DE60012711D1 (de) 2004-09-09
DE60012711T2 DE60012711T2 (de) 2005-08-18

Family

ID=22424291

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60012711T Expired - Lifetime DE60012711T2 (de) 1999-03-26 2000-03-24 Adjuvanszusammensetzungen zur erhöhung der immunantwort auf polynukleotid-basierende impfstoffe
DE60039198T Expired - Fee Related DE60039198D1 (de) 1999-03-26 2000-03-24 Adjuvanszusammensetzungen zur Erhöhung der Immunantwort bezüglich Polynukleotid-basierenden Impfstoffen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60039198T Expired - Fee Related DE60039198D1 (de) 1999-03-26 2000-03-24 Adjuvanszusammensetzungen zur Erhöhung der Immunantwort bezüglich Polynukleotid-basierenden Impfstoffen

Country Status (10)

Country Link
US (7) US6586409B1 (de)
EP (2) EP1165140B1 (de)
JP (2) JP4800485B2 (de)
AT (3) ATE549032T1 (de)
CA (1) CA2365416C (de)
DE (2) DE60012711T2 (de)
DK (1) DK1459766T3 (de)
ES (1) ES2308069T3 (de)
HK (1) HK1121382A1 (de)
WO (1) WO2000057917A2 (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105574B1 (en) 1999-03-26 2006-09-12 Vical Incorporated Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
US5641665A (en) * 1994-11-28 1997-06-24 Vical Incorporated Plasmids suitable for IL-2 expression
US20020088014A1 (en) * 1996-05-31 2002-07-04 Xiangming Fang Minimal adenovirus mediated recombinant vaccine
JP2001523480A (ja) * 1997-11-20 2001-11-27 バイカル インコーポレイテッド サイトカイン発現ポリヌクレオチドおよびそれらの組成物を用いた癌の処置
WO2000057917A2 (en) * 1999-03-26 2000-10-05 Vical Incorporated Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
US7078388B2 (en) * 2000-01-21 2006-07-18 Merial DNA vaccines for farm animals, in particular bovines and porcines
EP1278551A2 (de) * 2000-04-21 2003-01-29 Vical Incorporated Zusammensetzungen und verfahren zur (in vivo) verabreichung der auf polynukleotiden-basierenden therapeutika
US20030162733A1 (en) * 2000-11-27 2003-08-28 Haynes Joel R. Nucleic acid adjuvants
US7598421B2 (en) 2002-05-08 2009-10-06 Ucl Biomedica Plc Materials for the delivery of biologically-active material to cells
GB0210538D0 (en) * 2002-05-08 2002-06-19 Univ London Lipids and gene delivery
US20070105799A1 (en) * 2002-09-10 2007-05-10 Vical Incorporated Codon-optimized polynucleotide-based vaccines against Bacillus anthracis infection
US7381422B2 (en) * 2002-12-23 2008-06-03 Vical Incorporated Method for producing sterile polynucleotide based medicaments
SI2311848T1 (sl) * 2002-12-23 2013-11-29 Vical Incorporated Cepiva proti okuĹľbi humanega citomegalovirusa z optimizacijo kodona, ki temeljijo na polinukleotidu
CA2508279A1 (en) * 2002-12-23 2004-07-22 Vical Incorporated Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes
US8080642B2 (en) 2003-05-16 2011-12-20 Vical Incorporated Severe acute respiratory syndrome DNA compositions and methods of use
US7504243B2 (en) 2004-03-19 2009-03-17 The United States Of America As Represented By The Department Of Health And Human Services Methods for the production of biliverdin
US7303881B2 (en) * 2004-04-30 2007-12-04 Pds Biotechnology Corporation Antigen delivery compositions and methods of use
CA2566355C (en) 2004-05-18 2014-04-15 Vical Incorporated Influenza virus vaccine composition and methods of use
ES2549669T3 (es) * 2004-06-15 2015-10-30 The New York Blood Center, Inc. Propiedades de coadyuvancia y potenciación inmunitaria de productos naturales de Onchocerca volvulus
WO2006060723A2 (en) * 2004-12-03 2006-06-08 Vical Incorporated Methods for producing block copolymer/amphiphilic particles
US20060177468A1 (en) * 2005-01-05 2006-08-10 Philadelphia Health and Education Corporation (d/b/a Drexel University College of Medicine Delivery vehicles, bioactive substances and viral vaccines
LT2351772T (lt) 2005-02-18 2016-10-10 Glaxosmithkline Biologicals Sa Baltymai ir nukleorūgštys iš su meningitu/sepsiu susijusių escherichia coli
EP1858919B1 (de) 2005-02-18 2012-04-04 Novartis Vaccines and Diagnostics, Inc. Immungene von uropathogenen escherichia coli
US7957507B2 (en) 2005-02-28 2011-06-07 Cadman Patrick F Method and apparatus for modulating a radiation beam
AU2006236905B2 (en) 2005-04-15 2010-06-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
US8232535B2 (en) 2005-05-10 2012-07-31 Tomotherapy Incorporated System and method of treating a patient with radiation therapy
EP1907968A4 (de) 2005-07-22 2009-10-21 Tomotherapy Inc Verfahren und system zur bewertung von qualitätssicherheitskriterien bei der verabreichung eines behandlungsplans
EP1906827A4 (de) 2005-07-22 2009-10-21 Tomotherapy Inc System und verfahren zur evaluierung der mittels eines strahlungstherapiesystems verabreichten dosis
US8229068B2 (en) 2005-07-22 2012-07-24 Tomotherapy Incorporated System and method of detecting a breathing phase of a patient receiving radiation therapy
US8442287B2 (en) 2005-07-22 2013-05-14 Tomotherapy Incorporated Method and system for evaluating quality assurance criteria in delivery of a treatment plan
EP1907066A4 (de) 2005-07-22 2009-10-21 Tomotherapy Inc System und verfahren zur verabreichung einer strahlentherapie auf ein sich bewegendes interessengebiet
KR20080044250A (ko) 2005-07-23 2008-05-20 토모테라피 인코포레이티드 갠트리 및 진료대의 조합된 움직임을 이용하는 방사선치료의 영상화 및 시행
US10842867B2 (en) 2005-11-04 2020-11-24 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
AU2007239095B2 (en) 2006-01-09 2012-05-03 The Regents Of The University Of California Immunostimulatory combinations for vaccine adjuvants
EP1976559B3 (de) 2006-01-27 2020-02-19 Seqirus UK Limited Influenzaimpfstoffe mit hämagglutinin und matrixproteinen
JP2009534303A (ja) 2006-03-24 2009-09-24 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー 冷蔵しないインフルエンザワクチンの保存
WO2007126825A2 (en) 2006-03-31 2007-11-08 Novartis Ag Combined mucosal and parenteral immunization against hiv
EP2035035A2 (de) 2006-06-09 2009-03-18 Novartis AG Immunogene zusammensetzungen für streptococcus agalactiae
EP2521786B1 (de) * 2006-07-20 2015-06-24 Vical Incorporated Zusammensetzungen zur impfung gegen hsv-2
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
JP2010500399A (ja) 2006-08-16 2010-01-07 ノバルティス アーゲー 尿路病原性大腸菌由来の免疫原
CA3016948A1 (en) 2006-09-11 2008-03-20 Seqirus UK Limited Making influenza virus vaccines without using eggs
WO2008127450A2 (en) * 2006-12-04 2008-10-23 Vical Incorporated Linear expression cassette vaccines
EA200900784A1 (ru) 2006-12-06 2009-12-30 Новартис Аг Вакцины, включающие антиген из четырех штаммов вируса гриппа
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
US8877206B2 (en) * 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
US20080274137A1 (en) * 2007-05-02 2008-11-06 Jean Christophe Francis Audonnet DNA plasmids having improved expression and stability
JP2010525812A (ja) 2007-05-02 2010-07-29 メリアル リミテッド 発現及び安定性が改善されたｄｎａプラスミド
EP2167480A2 (de) * 2007-05-23 2010-03-31 Vical Incorporated Zusammensetzungen und verfahren zur verbesserung der immunreaktionen auf impfstoffe
US20090004203A1 (en) * 2007-05-29 2009-01-01 Vical Incorporated Methods of treating measles infectious disease in mammals
EP2185191B1 (de) 2007-06-27 2012-09-12 Novartis AG Influenzaimpfstoffe mit geringem zusatz
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
WO2009129227A1 (en) 2008-04-17 2009-10-22 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
EP2429581B1 (de) * 2009-05-14 2015-08-05 Bayer Intellectual Property GmbH Verbesserte immunantwort bei vogelspezies
EP4218799A1 (de) 2009-07-15 2023-08-02 GlaxoSmithKline Biologicals S.A. Rsv-f-proteinzusammensetzungen und verfahren zur herstellung davon
WO2011149564A1 (en) 2010-05-28 2011-12-01 Tetris Online, Inc. Interactive hybrid asynchronous computer game infrastructure
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
KR20130100267A (ko) 2010-08-09 2013-09-10 시박스, 인크. 질환을 예방하기 위한 방법 및 조성물
RU2606855C2 (ru) 2010-12-22 2017-01-10 Байер Интеллектчуал Проперти Гмбх Повышение иммунного отклика у видов крупного рогатого скота
US10342862B2 (en) 2011-01-26 2019-07-09 Glaxosmithkline Biologicals, Sa RSV immunization regimen
LT3275892T (lt) 2011-05-13 2020-04-10 Glaxosmithkline Biologicals S.A. Struktūros prieš suliejimą rsv f antigenai
AU2013201121A1 (en) 2011-09-20 2013-04-04 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
WO2013106558A1 (en) * 2012-01-10 2013-07-18 Merial Limited Lipid based adjuvants for dna - plasmid vaccines
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
EP4091630A1 (de) 2012-09-21 2022-11-23 PDS Biotechnology Corporation Impfstoffe mit r-dotap
EP2962309B1 (de) 2013-02-26 2022-02-16 Accuray, Inc. Elektromagnetisch betätigter mehrblatt-kollimator
KR20160122849A (ko) 2014-02-28 2016-10-24 바이엘 애니멀 헬스 게엠베하 면역자극성 플라스미드
JP2018521109A (ja) 2015-07-31 2018-08-02 バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ａｎｉｍａｌ Ｈｅａｌｔｈ Ｇｍｂｈ ぶた種における免疫応答の増強
EP4092112A1 (de) 2015-11-13 2022-11-23 PDS Biotechnology Corporation Lipide als synthetische vektoren zur verbesserung der antigenverarbeitung und präsentation ex-vivo in der dendritischen zelltherapie
AU2016367712B2 (en) 2015-12-09 2021-10-07 Jingang Medicine (Australia) Pty Ltd Immunomodulating composition for treatment
CN105483076B (zh) * 2015-12-23 2019-01-25 中国科学院生物物理研究所 一种脂肪体的制备方法及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867195B1 (en) * 1989-03-21 2005-03-15 Vical Incorporated Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US20030186913A1 (en) 1990-03-21 2003-10-02 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
US6228844B1 (en) 1991-11-12 2001-05-08 Vical Incorporated Stimulating vascular growth by administration of DNA sequences encoding VEGF
US6706694B1 (en) 1990-03-21 2004-03-16 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US7105574B1 (en) * 1999-03-26 2006-09-12 Vical Incorporated Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
WO1994029469A2 (en) 1993-06-07 1994-12-22 Vical Incorporated Plasmids suitable for gene therapy
IL113817A (en) 1994-06-30 2001-03-19 Merck & Co Inc Polynucleotide for vaccination against the umbilical cord virus
US5641665A (en) * 1994-11-28 1997-06-24 Vical Incorporated Plasmids suitable for IL-2 expression
US5705385A (en) * 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
ATE285477T1 (de) 1995-06-07 2005-01-15 Inex Pharmaceutical Corp Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer
WO1997019675A2 (en) 1995-11-30 1997-06-05 Vical Incorporated Complex cationic lipids
US5994317A (en) 1996-04-09 1999-11-30 Vical Incorporated Quaternary cytofectins
US5861397A (en) 1996-10-03 1999-01-19 Vical Incorporated Piperazine based cytofectins
US6235310B1 (en) * 1997-04-04 2001-05-22 Valentis, Inc. Methods of delivery using cationic lipids and helper lipids
JP2001523480A (ja) * 1997-11-20 2001-11-27 バイカル インコーポレイテッド サイトカイン発現ポリヌクレオチドおよびそれらの組成物を用いた癌の処置
WO2000057917A2 (en) * 1999-03-26 2000-10-05 Vical Incorporated Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
US6696424B1 (en) 1999-05-28 2004-02-24 Vical Incorporated Cytofectin dimers and methods of use thereof
EP1278551A2 (de) 2000-04-21 2003-01-29 Vical Incorporated Zusammensetzungen und verfahren zur (in vivo) verabreichung der auf polynukleotiden-basierenden therapeutika
AU2002254174A1 (en) 2001-03-13 2002-09-24 Vical Incorporated Interferon-beta polynucleotide therapy for autoimmune and inflammatory diseases
KR20040081151A (ko) 2002-01-28 2004-09-20 제이에프이 스틸 가부시키가이샤 도장강판의 제조방법
US20070105799A1 (en) * 2002-09-10 2007-05-10 Vical Incorporated Codon-optimized polynucleotide-based vaccines against Bacillus anthracis infection
US7381422B2 (en) 2002-12-23 2008-06-03 Vical Incorporated Method for producing sterile polynucleotide based medicaments
CA2508279A1 (en) 2002-12-23 2004-07-22 Vical Incorporated Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes
SI2311848T1 (sl) 2002-12-23 2013-11-29 Vical Incorporated Cepiva proti okuĹľbi humanega citomegalovirusa z optimizacijo kodona, ki temeljijo na polinukleotidu
US8080642B2 (en) * 2003-05-16 2011-12-20 Vical Incorporated Severe acute respiratory syndrome DNA compositions and methods of use

Also Published As

Publication number Publication date
WO2000057917A2 (en) 2000-10-05
JP4800485B2 (ja) 2011-10-26
EP1165140B1 (de) 2004-08-04
US20030191082A1 (en) 2003-10-09
US20130295139A1 (en) 2013-11-07
ATE397942T1 (de) 2008-07-15
ATE272410T1 (de) 2004-08-15
DK1459766T3 (da) 2008-10-13
EP1955709A2 (de) 2008-08-13
ES2308069T3 (es) 2008-12-01
CA2365416A1 (en) 2000-10-05
HK1121382A1 (en) 2009-04-24
US8415317B2 (en) 2013-04-09
JP2007176954A (ja) 2007-07-12
US20080213306A1 (en) 2008-09-04
US20140065189A1 (en) 2014-03-06
DE60039198D1 (de) 2008-07-24
JP2002540173A (ja) 2002-11-26
CA2365416C (en) 2011-06-14
US20110165197A1 (en) 2011-07-07
US20080145387A1 (en) 2008-06-19
EP1955709A3 (de) 2008-08-20
DE60012711T2 (de) 2005-08-18
US7582613B2 (en) 2009-09-01
ATE549032T1 (de) 2012-03-15
WO2000057917A3 (en) 2001-01-04
US6586409B1 (en) 2003-07-01
EP1955709B1 (de) 2012-03-14
EP1165140A2 (de) 2002-01-02

Similar Documents

Publication Publication Date Title
DE60012711D1 (de) Adjuvanszusammensetzungen zur erhöhung der immunantwort auf polynukleotid-basierende impfstoffe
IL150602A0 (en) Proteosome influenza vaccine
NO20015073D0 (no) Vaksiner
PT1487485E (pt) Adjuvantes de imidazoquinolina para vacinas de adn
ATE270707T1 (de) Entepneumovirus und entsprechendes impfstoff
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
DK1404363T3 (da) Adjuvanssammensætning til mucosalt og injektionsfremførte vacciner
WO2002009746A8 (en) Vaccines comprising outer membrane vesciles from gram negative bacteria
DK0705109T4 (da) Adjuvanser til vacciner mod respiratorisk syncytialvirus
GB2386072A (en) Novel vaccine
GB0109297D0 (en) Vaccine
DK1259259T3 (da) Mucosal adjuvansformulering
CY1112658T1 (el) Εμβολια τα οποια περιεχουν αντιγονο μαgε συνδεομενο με θραυσμα πρωτεϊνης d
AU2001284354A1 (en) Immunological adjuvant compounds, compositions, and methods of use thereof
GEP20053446B (en) Adjuvant Combination Formulations
DE69922212D1 (de) Impfstoff enthaltend zytokin-induzierte heat shock proteine (hsp)
DK1074266T3 (da) Levende svækkede bakterier til anvendelse i vaccine
FR2809960B1 (fr) Composition adjuvante de la reponse immunitaire comprenant la proteine fha ou un fragment de la proteine fha sous forme libre, et composition immunogene ou vaccinale contenant une telle composition adjuvante
ATE374622T1 (de) Genetische impstoffe mit adjuvans
DE69942161D1 (de) Genetische Adjuvanz-Impfstoffe

Legal Events

Date Code Title Description
8364 No opposition during term of opposition